Discovery of a CK2α′-Biased ATP-Competitive Inhibitor from a High-Throughput Screen of an Allosteric-Inhibitor-Like Compound Library
ACS Chemical Neuroscience · 2024
DOI: 10.1021/acschemneuro.4c00062 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Neuroscience, 2024. Verfasst von Deepti Mudaliar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Institute for Therapeutics Discovery and Development, University of Minnesota, Minneapolis, Minnesota 55414, Unite…. Hauptthemen laut MEDLINE: Casein Kinase II, Adenosine Triphosphate, Protein Kinase Inhibitors, High-Throughput Screening Assays. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, National Institute of Neurological Disorders and Stroke.
Abstract (Originalsprache)
Protein kinase CK2 is a holoenzyme composed of two regulatory subunits (CK2β) and two catalytic subunits (CK2α and CK2α'). CK2 controls several cellular processes, including proliferation, inflammation, and cell death. However, CK2α and CK2α' possess different expression patterns and substrates and therefore impact each of these processes differently. Elevated CK2α participates in the development of cancer, while increased CK2α' has been associated with neurodegeneration, especially Huntington's disease (HD). HD is a fatal disease for which no effective therapies are available. Genetic deletion of CK2α' in HD mouse models has ameliorated neurodegeneration. Therefore, pharmacological inhibition of CK2α' presents a promising therapeutic strategy for treating HD. However, current CK2 inhibitors are unable to discriminate between CK2α and CK2α' due to their high structural homology, especially in the targeted ATP-binding site. Using computational analyses, we found a potential type IV ("D" pocket) allosteric site that contained different residues between CK2α and CK2α' and was distal from the ATP-binding pocket featured in both kinases. We decided to look for allosteric modulators that might interact in a biased fashion with the type IV pocket on both CK2α and CK2α'. We screened a commercial library containing ∼29,000 allosteric-kinase-inhibitor-like compounds using a CK2α' activity-dependent ADP-Glo Kinase assay. Obtained hits were counter-screened against CK2α using the ADP-Glo Kinase assay, revealing two CK2α'-biased compounds. These two compounds might serve as the basis for further medicinal chemistry optimization for the potential treatment of HD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, Institute for Therapeutics Discovery and Development, University of Minnesota, Minneapolis, Minnesota 55414, United States.
- Department of Neuroscience, School of Medicine, University of Minnesota, Minneapolis, Minnesota 55414, United States.
ORCID-Profile: Jon Hawkinson, Henry Wong, Michael A Walters, Rocio Gomez-Pastor
Förderung
- NINDS NIH HHS
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Mudaliar, D., Mansky, R. H., White, A., Baudhuin, G., Hawkinson, J., Wong, H., Walters, M. A., & Gomez-Pastor, R. (2024). Discovery of a CK2α′-Biased ATP-Competitive Inhibitor from a High-Throughput Screen of an Allosteric-Inhibitor-Like Compound Library. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.4c00062
Vancouver
Mudaliar D, Mansky RH, White A, Baudhuin G, Hawkinson J, Wong H, et al. Discovery of a CK2α′-Biased ATP-Competitive Inhibitor from a High-Throughput Screen of an Allosteric-Inhibitor-Like Compound Library. ACS Chemical Neuroscience. 2024. doi:10.1021/acschemneuro.4c00062
BibTeX
@article{Mudaliar2024,
author = {Mudaliar, Deepti and Mansky, Rachel H and White, Angel and Baudhuin, Grace and Hawkinson, Jon and Wong, Henry and Walters, Michael A and Gomez-Pastor, Rocio},
title = {Discovery of a CK2α′-Biased ATP-Competitive Inhibitor from a High-Throughput Screen of an Allosteric-Inhibitor-Like Compound Library},
journal = {ACS Chemical Neuroscience},
year = {2024},
doi = {10.1021/acschemneuro.4c00062}
}
EUVIMED